Deepa Jagadeesh

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Kieron Dunleavy, Michelle A. Fanale, Jeremy S. Abramson et al. · The Lancet Haematology · 2018 · 226 citations

Hematological Malignancy, Lymphoid Neoplasia, Single-arm Phase 2 +9

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era

Andrew M. Evens, Sylvain Choquet, Aimee Kroll‐Desrosiers et al. · American Journal of Transplantation · 2013 · 181 citations · Full text

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Steven M. Horwitz, Stephen M. Ansell, Weiyun Z. Ai et al. · Journal of the National Comprehensive Cancer Network · 2022 · 153 citations · Full text

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Mark Roschewski, Kieron Dunleavy, Jeremy S. Abramson et al. · Journal of Clinical Oncology · 2020 · 146 citations · Full text

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

Jeremy S. Abramson, Tatyana Feldman, Aimee Kroll‐Desrosiers et al. · Annals of Oncology · 2014 · 137 citations · Full text

Hematological Malignancy, Frontline Therapy, Lymphoid Neoplasia +10